Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63814
HIGH PRODUCTION MBL2 POLYMORPHISMS PROTECT AGAINST COVID-19 COMPLICATIONS IN CRITICALLY ILL PATIENTS: A RETROSPECTIVE COHORT STUDY
Sistema complemento
Lectina ligadora de manose
Lectina de ligação a manana
Polimorfismo
SARS-CoV-2
Complement system
Mannose-binding lectin
Mannan-binding lectin
Polymorphism
SARS-CoV-2
Author
Affilliation
Universidade Federal do Vale do São Francisco. Programa de Pós-graduação em Biociências. Petrolina, PE, Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Ciências Farmacêuticas. Petrolina, PE, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Medicina. Petrolina, PE. Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Medicina. Petrolina, PE. Brasil.
Universidade Federal do Vale do São Francisco. Programa de Pós-graduação em Biociências. Petrolina, PE, Brasil / Universidade Federal do Vale do São Francisco. Colegiado de Ciências Farmacêuticas. Petrolina, PE, Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Ciências Farmacêuticas. Petrolina, PE, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Medicina. Petrolina, PE. Brasil.
Universidade Federal do Vale do São Francisco. Colegiado de Medicina. Petrolina, PE. Brasil.
Universidade Federal do Vale do São Francisco. Programa de Pós-graduação em Biociências. Petrolina, PE, Brasil / Universidade Federal do Vale do São Francisco. Colegiado de Ciências Farmacêuticas. Petrolina, PE, Brasil.
Abstract
Mannose-binding lectin (MBL) binds to SARS-CoV-2, inhibits infection of susceptible cells, and activates the complement system via the lectin pathway. In this study, we investigated the association of MBL2 polymorphisms with the risk of hospitalization and clinical worsening in patients with COVID-19. A total of 550 patients with COVID-19 were included (94 non-hospitalized and 456 hospitalized). Polymorphisms in MBL2 exon 1 (codons 52, 54 and 57) and promoter region (−550, −221, and +4) were determined by real-time PCR. MBL and complement proteins were measured by Luminex. A higher frequency of the H/H genotype and the HYPA haplotype was observed in non-hospitalized patients when compared to hospitalized. In addition, critically ill patients carrying haplotypes associated with high MBL levels (HYPA/HYPA + HYPA/LYPA + HYPA/LYQA + LYPA/LYQA + LYPA/LYPA + LYQA/LYQA + LXPA/HYPA + LXPA/LYQA + LXPA/LYPA) were protected against lower oxygen saturation levels (P = 0.02), use of invasive ventilation use (P = 0.02, OR 0.38), and shock (P = 0.01, OR 0.40), independent of other potential confounders adjusted by multivariate analysis. Our results suggest that variants in MBL2 associated with high MBL levels may play a protective role in the clinical course of COVID-19.
Keywords in Portuguese
Imunidade inataSistema complemento
Lectina ligadora de manose
Lectina de ligação a manana
Polimorfismo
SARS-CoV-2
Keywords
Innate immunityComplement system
Mannose-binding lectin
Mannan-binding lectin
Polymorphism
SARS-CoV-2
Share